NLS Pharma Pins Hopes On Ex-Obesity Drug For ADHD
Emerging Company Profile: NLS Pharma wants to develop novel treatments for ADHD, sleep disorders and cognitive impairments. Its big hope is mazindol CR, for which it has just announced promising Phase II data. The firm explains what is next.
You may also be interested in...
Sunovion is pressing ahead with plans for an FDA filing for its ADHD drug dasotraline in adult and children patients despite ongoing uncertainty over the drug's efficacy in the older grouping.
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.